Login to Your Account



Clinic Roundup


Tuesday, May 22, 2012
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said it reached its patient recruitment goal for a Phase IIb study of CPP-109 vigabatrin, with an estimated 210 cocaine-dependent subjects enrolled following final screening this week. Top-line data are expected in the first quarter of 2013. CPP-109 is a GABA analogue that has fast-track status in the U.E.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription